In ALK+ NSCLC, for instance, comparing crizotinib with standard chemotherapy in the second-line setting resulted in an improved overall response rate (65% vs. 20%, respectively), a shorter response time (6.3 vs. 12.6 weeks), and an improved median progression-free survival (7.7 vs. 3.0 months) with crizotinib [15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.